Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation

Pharmacology, Biochemistry, and Behavior
K Lee, C Kornetsky

Abstract

The effects of fluoxetine on rewarding brain stimulation were determined in eight Wistar rats using a rate-independent discrete-trial threshold measure. Rats were implanted with bipolar, stainless steel electrodes either into the ventral tegmental area (VTA) or medial forebrain bundle (MFB). Acute administration of fluoxetine significantly raised the reward threshold (decreased sensitivity) at doses of 2.5, 5.0, 10.0, and 20.0 mg/kg, i.p., without altering latency of response. There were no significant differences between VTA and MFB groups. To determine the effects of chronic treatment, daily injections of 5.0 mg/kg fluoxetine were administered to rats for 21 days. Chronic treatment of fluoxetine continued to significantly elevate reward thresholds with no evidence of tolerance. The results of these experiments suggest that fluoxetine does not possess abuse potential and that serotonin produces an inhibitory effect on the mesolimbic dopaminergic reward system. Furthermore, these results suggest that the antidepressant effects of fluoxetine are not the direct result of excitation of brain reward systems, at least in the same manner as abused substances, for example, cocaine.

References

Apr 1, 1978·Pharmacology, Biochemistry, and Behavior·R U EspositoC Kornetsky
Jan 1, 1978·Annual Review of Pharmacology and Toxicology·H C Fibiger
May 1, 1992·Trends in Pharmacological Sciences·G F Koob
Jul 8, 1992·Annals of the New York Academy of Sciences·R A WiseW Trojniar
Jan 1, 1991·Journal of Neural Transmission. General Section·A M MontgomeryL J Herberg
May 1, 1991·Pharmacology, Biochemistry, and Behavior·D A ValentinoR L Dufresne
Jul 1, 1988·Brain Research Bulletin·X M Guan, W J McBride
Oct 1, 1988·Pharmacology, Biochemistry, and Behavior·B D McCarter, L Kokkinidis
Apr 23, 1974·Psychopharmacologia·S BoseS N Pradhan
Sep 1, 1969·European Journal of Pharmacology·S B Ross, A L Renyi
Oct 20, 1980·Life Sciences·S C Gerson, R J Baldessarini
Sep 1, 1995·Pharmacology, Biochemistry, and Behavior·P J FletcherJ S Yeomans
Jun 1, 1994·Pharmacology, Biochemistry, and Behavior·A PlaznikM Nazar
Feb 1, 1994·Mayo Clinic Proceedings·J A TinsleyM A Palmen
Aug 15, 1995·European Journal of Pharmacology·J Ichikawa, H Y Meltzer

❮ Previous
Next ❯

Citations

May 5, 2007·Psychopharmacology·Brian HitsmanDonald Hedeker
Mar 29, 2001·Pharmacology, Biochemistry, and Behavior·M TrzcińskaJ W Babich
Oct 12, 2002·Pharmacology, Biochemistry, and Behavior·J C WinterR A Rabin
Jul 27, 1999·Pharmacology, Biochemistry, and Behavior·A T Konkle, C Bielajew
Jun 1, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·C A NaranjoU E Busto
Mar 16, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amy Cecilia SandersXiaoxi Zhuang
Sep 1, 2007·Behavioural Pharmacology·Jessica A Valluzzi, KinHo Chan
Aug 3, 2000·Alcoholism, Clinical and Experimental Research·F Chen, A J Lawrence
Jul 6, 2004·Drugs·David A GorelickZheng-Xiong Xi
Jan 30, 2010·Neuroscience·G S KranzR Lanzenberger
Feb 23, 2010·Biological Psychiatry·Sergio D IñiguezCarlos A Bolaños-Guzmán
Jan 17, 2015·European Journal of Pharmacology·S Mechiel KorteBerend Olivier
Jan 17, 2003·Psychopharmacology·Jeffrey J BurmeisterJanet L Neisewander
Apr 30, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caleb J Browne, Paul J Fletcher
Jan 22, 2013·The Journal of Pain : Official Journal of the American Pain Society·Marisa B RosenbergS Stevens Negus
Dec 14, 2004·Journal of Psychiatric Research·Mert CeyhanI Tayfun Uzbay
Dec 23, 2008·Behavioural Brain Research·Kuei Y TsengBarbara K Lipska
Dec 8, 2004·Epilepsy & Behavior : E&B·Danielle Silveira MacêdoFrancisca Cléa Florenço de Sousa
Oct 13, 2005·Pharmacology, Biochemistry, and Behavior·F O GoeldnerR Boerngen-Lacerda
Jul 1, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hao-Wei ShenIchiro Sora
Jan 14, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brian HitsmanDonald Hedeker
Jun 29, 2014·Pharmacological Reviews·S Stevens Negus, Laurence L Miller
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Stephen D MagueWilliam A Carlezon
Jan 23, 2003·Drug and Alcohol Review·Angela J Dean

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Pharmacology, Biochemistry, and Behavior
D A ValentinoR L Dufresne
Integrative Physiological and Behavioral Science : the Official Journal of the Pavlovian Society
S Wolf
© 2022 Meta ULC. All rights reserved